{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:55:04Z","timestamp":1793894104847,"version":"4.8.0"},"reference-count":282,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304291"],"award-info":[{"award-number":["82304291"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371180"],"award-info":[{"award-number":["82371180"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901163"],"award-info":[{"award-number":["81901163"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173716"],"award-info":[{"award-number":["82173716"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018635","name":"Thousand Young Talents Program of China","doi-asserted-by":"publisher","award":["QNQR-2021-02"],"award-info":[{"award-number":["QNQR-2021-02"]}],"id":[{"id":"10.13039\/501100018635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2025YC29"],"award-info":[{"award-number":["2025YC29"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118952","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:23:33Z","timestamp":1778891013000},"page":"118952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["New drugs approved by the FDA in 2025: Synthesis and clinical applications"],"prefix":"10.1016","volume":"315","author":[{"given":"Wenjie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118952_bib2","article-title":"2025 FDA approvals","author":"Mullard","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118952_bib3","series-title":"Advancing Health Through Innovation: New Drug Therapy Approvals 2025","year":"2026"},{"key":"10.1016\/j.ejmech.2026.118952_bib4","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO-25-00112","article-title":"Efficacy and safety of avutometinib \u00b1 defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"43","author":"Banerjee","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib5","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.23.01134","article-title":"ONC201 (Dordaviprone) in recurrent H3 K27M-Mutant diffuse midline glioma","volume":"42","author":"Arrillaga-Romany","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib7","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib8","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","article-title":"Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial","volume":"9","author":"Klug","year":"2024","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ejmech.2026.118952_bib10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jacc.2018.04.082","article-title":"Etripamil nasal spray for rapid conversion of supraventricular tachycardia to sinus rhythm","volume":"72","author":"Stambler","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2026.118952_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa2314192","article-title":"Oral sebetralstat for On-Demand treatment of hereditary angioedema attacks","volume":"391","author":"Riedl","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib13","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib14","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","article-title":"Nerandomilast in patients with idiopathic pulmonary fibrosis","volume":"392","author":"Richeldi","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118952_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0140-6736(25)02331-1","article-title":"Zoliflodacin shows benefit as an oral treatment for uncomplicated gonorrhoea","volume":"407","author":"Workowski","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118952_bib18","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(24)01556-3","article-title":"Effects of oral sepiapterin on blood phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial","volume":"404","author":"Muntau","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118952_bib19","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118952_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2402478","article-title":"Efficacy and safety of donidalorsen for hereditary angioedema","volume":"391","author":"Riedl","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib21","article-title":"Long lasting response to the combination of Avutometinib and defactinib after progression on binimetinib in a patient with recurrent low grade serous ovarian carcinoma \u2212 A case report","volume":"63","author":"Ettorre","year":"2026","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ejmech.2026.118952_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2025.06.022","article-title":"The RAS-MEK-ERK pathway in low-grade serous ovarian cancer","volume":"200","author":"Stover","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib23","doi-asserted-by":"crossref","first-page":"14382","DOI":"10.1021\/acs.jmedchem.0c01248","article-title":"Progress in the development of small molecular inhibitors of Focal Adhesion Kinase (FAK)","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116246","article-title":"Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders","volume":"224","author":"Yang","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118952_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","article-title":"Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer","volume":"139","author":"Gerber","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2026.118952_bib26","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2021.05.018","article-title":"Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation","volume":"75","author":"Song","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2026.118952_bib27","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.3390\/ijms26188924","article-title":"Preclinical efficacy of the Estrogen receptor degrader fulvestrant in combination with RAF\/MEK clamp avutometinib and FAK inhibitor in a low-grade serous ovarian cancer animal model with acquired resistance to chemotherapy and aromatase inhibitor","volume":"26","author":"Demirkiran","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118952_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1021\/ml400379x","article-title":"Optimizing the physicochemical properties of Raf\/MEK inhibitors by nitrogen scanning","volume":"5","author":"Aoki","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118952_bib29","series-title":"Synthesis Method for Aminopyrimidine FAK Inhibitor Compound, July 21","author":"Du","year":"2022"},{"key":"10.1016\/j.ejmech.2026.118952_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40265-025-02252-3","article-title":"Dordaviprone: first approval","volume":"86","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib31","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.1002\/anie.201402133","article-title":"Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL","volume":"53","author":"Jacob","year":"2014","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.118952_bib32","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/0008-5472.CAN-24-2608","article-title":"Imlunestrant is an oral, brain-penetrant selective estrogen receptor degrader with potent antitumor activity in ESR1 wild-type and mutant breast cancer","volume":"85","author":"Bhagwat","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118952_bib33","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1158\/1078-0432.CCR-24-2113","article-title":"A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-Positive, HER2-Negative early breast cancer: results from the EMBER-2 study","volume":"30","author":"Neven","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118952_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40265-025-02266-x","article-title":"Imlunestrant: first approval","volume":"86","author":"Keam","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ygyno.2024.10.006","article-title":"Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent\/advanced ER-positive endometrioid endometrial cancer: results from the phase 1a\/1b EMBER study","volume":"191","author":"Yonemori","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib36","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1021\/acs.jmedchem.3c00136","article-title":"Targeting the estrogen receptor for the treatment of breast cancer: recent advances and challenges","volume":"66","author":"Rej","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib37","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.1021\/acs.jmedchem.8b00921","article-title":"Identification of an orally bioavailable chromene-based selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in a model of tamoxifen-resistant breast cancer","volume":"61","author":"Nagasawa","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/acsmedchemlett.8b00414","article-title":"Maximizing ER-\u03b1 degradation maximizes activity in a tamoxifen-resistant breast cancer model: identification of GDC-0927","volume":"10","author":"Kahraman","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118952_bib39","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2174\/0929867053764662","article-title":"Non-steroidal subtype selective estrogens","volume":"12","author":"Veeneman","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib40","series-title":"INLURIYO (Imlunestrant) Prescribing Information","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118952_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.11.018","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial","volume":"37","author":"Jhaveri","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib42","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.188051","article-title":"Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor\u2013positive breast cancer","volume":"10","author":"Sherman","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2026.118952_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.1021","article-title":"A phase 1a\/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER plus) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): monotherapy results from EMBER","volume":"40","author":"Jhaveri","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib44","series-title":"Processes for the Preparation of Selective Estrogen Receptor Degraders, August 3","author":"Delgado","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118952_bib46","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40265-025-02190-0","article-title":"Mirdametinib: first approval","volume":"85","author":"Hoy","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib47","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-Associated plexiform neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115236","article-title":"Optically activated MEK1\/2 inhibitors (Opti-MEKi) as potential antimelanoma agents","volume":"251","author":"Hao","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib49","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-Related plexiform neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib50","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/13543784.2025.2558656","article-title":"Mirdametinib, an FDA-approved MEK1\/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas","volume":"34","author":"Oztosun","year":"2025","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib51","article-title":"Exth-102. Plasma and cerebrospinal fluid (Csf) pharmacokinetics (Pk) of mirdametinib in a non-human primate (Nhp) model","volume":"24","author":"McCully","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib52","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jtho.2024.09.017","article-title":"PL04.03 safety and efficacy of BAY 2927088 in patients with HER2-Mutant NSCLC: Expansion cohort from the phase I\/II SOHO-01 study","volume":"19","author":"Le","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib53","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8598","article-title":"Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: results from an expansion cohort of the SOHO-01 phase I\/II study","volume":"42","author":"Girard","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib54","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.8504","article-title":"Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but na\u00efve to HER2-targeted therapy or had not received any treatment for advanced disease","volume":"43","author":"Loong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2625","article-title":"Molecular factors and ctDNA dynamics associated with clinical outcomes in patients with HER2-mutant NSCLC treated with sevabertinib (BAY 2927088): exploratory analysis of the SOHO-01 study","volume":"36","author":"Girard","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib56","series-title":"4H-Pyrrolo[3,2-c]pyridin-4-one Compounds, October 29","author":"Siegel","year":"2020"},{"key":"10.1016\/j.ejmech.2026.118952_bib57","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.tips.2025.10.009","article-title":"Sunvozertinib (Zegfrovy): an oral EGFR inhibitor that irreversibly targets exon20ins in NSCLC","volume":"46","author":"Niu","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.118952_bib58","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/cancers13051120","article-title":"Structural basis for the functional changes by EGFR Exon 20 insertion mutations","volume":"13","author":"Tamirat","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.118952_bib59","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/2159-8290.CD-21-1615","article-title":"Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR Exon 20 insertion mutations","volume":"12","author":"Wang","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118952_bib60","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1200\/JCO.2024.42.16_suppl.8513","article-title":"A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: primary analysis of WU-KONG1 study","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib61","series-title":"Novel Pharmaceutical Salts and Polymorphic Forms of an Erbb and Btk Inhibitor, January 25","author":"Zheng","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118952_bib62","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40265-025-02256-z","article-title":"Taletrectinib: first approval","volume":"86","author":"Hoy","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib63","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41467-019-11496-z","article-title":"The new-generation selective ROS1\/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models","volume":"10","author":"Katayama","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118952_bib64","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1200\/JCO-25-00275","article-title":"Taletrectinib in ROS1+ non-small cell lung cancer: trust","volume":"43","author":"Perol","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib65","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.24.00731","article-title":"Efficacy and safety of taletrectinib in Chinese patients with ROS1+ non-small cell lung cancer: the phase II TRUST-I study","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib66","series-title":"Method for Producing 3,6-disubstituted-imidazo[1,2-b]pyridazine Compounds, November 23","author":"Zhou","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118952_bib68","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00262-024-03740-3","article-title":"Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells","volume":"73","author":"El-Serafi","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejmech.2026.118952_bib69","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/sj.bjc.6690043","article-title":"DNA alkylation and interstrand cross-linking by treosulfan","volume":"79","author":"Hartley","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118952_bib70","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7046","article-title":"Better survival with fludarabine and timed sequential busulfan regimen in older patients with AML\/MDS","volume":"35","author":"Popat","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib71","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-203266","article-title":"Treosulfan Vs busulfan as part of clofarabine based reduced intensity conditioning regimen before allotransplant for Myeloid malignancies","volume":"144","author":"Prin Felix","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118952_bib72","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/ijgc-2021-002395","article-title":"Treosulfan in platinum-resistant ovarian cancer","volume":"31","author":"Olesen","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118952_bib73","series-title":"A Process for the Preparation of Treosulfan, March 7","author":"Sharma","year":"2019"},{"key":"10.1016\/j.ejmech.2026.118952_bib74","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40265-025-02191-z","article-title":"Vimseltinib: first approval","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128928","article-title":"Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)","volume":"74","author":"Caldwell","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118952_bib76","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1158\/1535-7163.MCT-21-0361","article-title":"Vimseltinib: a precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages","volume":"20","author":"Smith","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118952_bib77","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-24-0103","article-title":"CSF1R inhibition in patients with advanced solid tumors or tenosynovial giant cell tumor: a phase I study of vimseltinib","volume":"30","author":"Gelderblom","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118952_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51211-y","article-title":"Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor","volume":"9","author":"Verspoor","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118952_bib79","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells","volume":"103","author":"West","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.118952_bib80","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","article-title":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Gelderblom","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118952_bib81","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118952_bib82","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib83","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1038\/s41375-022-01707-w","article-title":"Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1","volume":"36","author":"Fiskus","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.118952_bib84","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in relapsed or refractory NPM1-Mutated AML","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib85","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118952_bib86","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3324\/haematol.2022.282160","article-title":"Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax","volume":"108","author":"Rausch","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2026.118952_bib87","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.clinthera.2025.12.010","article-title":"KOMZIFTI (Ziftomenib)","volume":"48","author":"Beninger","year":"2026","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejmech.2026.118952_bib88","series-title":"Process of making a menin-mll inhibitor","author":"Bakale","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118952_bib89","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-Mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib91","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2159-8290.CD-24-0306","article-title":"Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-Driven cancers","volume":"15","author":"Wilding","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118952_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102613","article-title":"Updated data from Beamion LUNG-1, a phase (ph) Ia\/b trial of the HER2-specific tyrosine kinase inhibitor (TKI), zongertinib (BI 1810631), in patients (pts) with HER2 mutation-positive (m+) NSCLC","volume":"9","author":"Wu","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejmech.2026.118952_bib93","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1073\/pnas.0808930106","article-title":"HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy","volume":"106","author":"Perera","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118952_bib94","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41571-025-01030-0","article-title":"Promising results with zongertinib in advanced-stage HER2-mutant NSCLC","volume":"22","author":"Romero","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib95","series-title":"Crystalline Forms of a HER2 Inhibitor","author":"Werthmann","year":"2024"},{"key":"10.1016\/j.ejmech.2026.118952_bib96","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40262-025-01481-9","article-title":"Effect of hepatic impairment or renal impairment on the pharmacokinetics of aficamten","volume":"64","author":"Xu","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2026.118952_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.03.040","article-title":"Aficamten treatment for symptomatic obstructive hypertrophic cardiomyopathy","volume":"13","author":"Saberi","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejmech.2026.118952_bib98","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib99","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s44161-024-00505-0","article-title":"Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy","volume":"3","author":"Hartman","year":"2024","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.ejmech.2026.118952_bib100","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jacc.2024.09.003","article-title":"Impact of aficamten on disease and symptom burden in obstructive hypertrophic cardiomyopathy","volume":"84","author":"Maron","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2026.118952_bib101","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jchf.2024.11.011","article-title":"Aficamten vs metoprolol for obstructive hypertrophic cardiomyopathy","volume":"13","author":"Garcia-Pavia","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejmech.2026.118952_bib102","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib103","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jacc.2024.08.014","article-title":"Effect of aficamten on health status outcomes in obstructive hypertrophic cardiomyopathy","volume":"84","author":"Sherrod","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2026.118952_bib104","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/ijms26030944","article-title":"Elamipretide: a review of its structure, mechanism of action, and therapeutic potential","volume":"26","author":"Tung","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118952_bib105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-025-02269-8","article-title":"Elamipretide: first approval","volume":"86","author":"Shirley","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib106","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10741-020-10031-3","article-title":"Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide","volume":"26","author":"Sabbah","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ejmech.2026.118952_bib107","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jacbts.2018.12.005","article-title":"Elamipretide improves mitochondrial function in the failing human heart","volume":"4","author":"Chatfield","year":"2019","journal-title":"JACC, Basic Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.118952_bib108","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1212\/WNL.0000000000005255","article-title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","volume":"90","author":"Karaa","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2026.118952_bib109","article-title":"Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide, January 7","author":"Zhao","year":"2016","journal-title":"World Intellectual Property Organization (WIPO)"},{"key":"10.1016\/j.ejmech.2026.118952_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2019.05.003","article-title":"Etripamil: intranasal calcium channel blocker: a novel noninvasive modality in the treatment of paroxysmal supraventricular tachycardia","volume":"46","author":"Raja","year":"2021","journal-title":"Curr. Probl. Cardiol."},{"issue":"798","key":"10.1016\/j.ejmech.2026.118952_bib111","article-title":"Etripamil - a multichannel modulator to suppress atrial fibrillation","volume":"27","author":"Prueser","year":"2025","journal-title":"Europace"},{"key":"10.1016\/j.ejmech.2026.118952_bib112","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.123.011681","article-title":"Self-administered etripamil nasal spray relieved symptoms, decreased heart rate, and reduced medical interventions during atrioventricular nodal-dependent paroxysmal supraventricular tachycardia","volume":"17","author":"Stambler","year":"2024","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.ejmech.2026.118952_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543784.2020.1703180","article-title":"Etripamil nasal spray: an investigational agent for the rapid termination of paroxysmal supraventricular tachycardia (SVT)","volume":"29","author":"Kashou","year":"2019","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib114","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.jacc.2024.03.384","article-title":"Etripamil nasal spray for recurrent paroxysmal supraventricular tachycardia conversion","volume":"83","author":"Ip","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2026.118952_bib116","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(23)00776-6","article-title":"Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial","volume":"402","author":"Stambler","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118952_bib117","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1161\/CIRCEP.123.012567","article-title":"Multicenter, phase 2, randomized controlled study of the efficacy and safety of Etripamil nasal spray for the acute reduction of rapid ventricular rate in patients with symptomatic atrial fibrillation (ReVeRA-201)","volume":"16","author":"Camm","year":"2023","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.ejmech.2026.118952_bib118","series-title":"Method for Preparing a Drug Used for Paroxysmal Supraventricular Tachycardia, October 16","author":"Pagliari","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118952_bib119","doi-asserted-by":"crossref","DOI":"10.1007\/s40272-025-00734-1","article-title":"Doxecitine and doxribtimine: first approval","volume":"28","author":"Blair","year":"2026","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109159","article-title":"Doxecitine and doxribtimine treatment in an adult patient with thymidine kinase 2 deficiency","volume":"145","author":"Chow","year":"2025","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejmech.2026.118952_bib121","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.clinthera.2024.06.006","article-title":"Pharmacokinetics and safety of a 1:1 mixture of doxecitine and doxribtimine: Open-label phase 1 single ascending dose and food effect studies in healthy adults","volume":"46","author":"Mittur","year":"2024","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejmech.2026.118952_bib122","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/15257770.2024.2437038","article-title":"Convenient syntheses of isotopically labeled pyrimidine 2\u2019-deoxynucleosides and their 5-hydroxy oxidation products","volume":"44","author":"Gao","year":"2024","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.ejmech.2026.118952_bib123","series-title":"A Method for Preparing \u03b2-thymidine","author":"Li","year":"2016"},{"key":"10.1016\/j.ejmech.2026.118952_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.155116","article-title":"PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study","volume":"128","author":"Bratkovic","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2026.118952_bib125","article-title":"P029: the effects of the pharmacological chaperone sepiapterin on phenylalanine hydroxylase activity of common variants in phenylketonuria","volume":"1","author":"Gersting","year":"2023","journal-title":"Genet Med Open"},{"key":"10.1016\/j.ejmech.2026.118952_bib126","doi-asserted-by":"crossref","first-page":"30686","DOI":"10.1074\/jbc.M110.124016","article-title":"Activation of phenylalanine hydroxylase induces positive cooperativity toward the natural cofactor","volume":"285","author":"Gersting","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib127","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13023-025-03840-y","article-title":"Current state of the treatment landscape of phenylketonuria","volume":"20","author":"Nulmans","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejmech.2026.118952_bib129","series-title":"European Patent Office (EPO)","article-title":"Method for producing sepiapterin and tetrahydrolactoylpterin","author":"Yoshino","year":"2015"},{"key":"10.1016\/j.ejmech.2026.118952_bib130","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s40265-025-02214-9","article-title":"Gepotidacin: first approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib131","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118952_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115413","article-title":"Antibiotics with novel mode of action as new weapons to fight antimicrobial resistance","volume":"256","author":"Ruggieri","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib133","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1021\/acsinfecdis.5c00497","article-title":"Mechanism of action of gepotidacin: well-balanced dual-targeting against Neisseria gonorrhoeae gyrase and topoisomerase IV in cells and in vitro","volume":"11","author":"Oviatt","year":"2025","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118952_bib134","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-18","article-title":"Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae","volume":"62","author":"Scangarella-Oman","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118952_bib135","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118952_bib136","series-title":"Tricyclic Nitrogen Containing Compounds for Treating Neisseria Gonorrhoea Infection, February 25","author":"Widdowson","year":"2016"},{"key":"10.1016\/j.ejmech.2026.118952_bib137","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1021\/acsinfecdis.4c00438","article-title":"Interactions between Zoliflodacin and Neisseria gonorrhoeae gyrase and topoisomerase IV: enzymological basis for cellular targeting","volume":"10","author":"Collins","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118952_bib138","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.3390\/ijms24021634","article-title":"A 2.8 A structure of Zoliflodacin in a DNA cleavage complex with Staphylococcus aureus DNA gyrase","volume":"24","author":"Morgan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118952_bib139","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1128\/AAC.04456-14","article-title":"Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae","volume":"59","author":"Alm","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118952_bib140","doi-asserted-by":"crossref","first-page":"20984","DOI":"10.1074\/jbc.M115.663534","article-title":"Inhibition of Neisseria gonorrhoeae type II topoisomerases by the novel spiropyrimidinetrione AZD0914","volume":"290","author":"Kern","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib141","article-title":"Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial type II topoisomerases","volume":"5","author":"Basarab","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118952_bib142","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(25)01953-1","article-title":"Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial","volume":"407","author":"Luckey","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118952_bib143","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-Dose Zoliflodacin (ETX0914) for treatment of Urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib144","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00284-024-03761-2","article-title":"Efficacy of Zoliflodacin, a spiropyrimidinetrione antibiotic, against gram-negative pathogens","volume":"81","author":"Oyardi","year":"2024","journal-title":"Curr. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118952_bib145","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13075","article-title":"Evaluating the potency of zoliflodacin against Helicobacter pylori: in vitro activity and conserved GyrB target","volume":"29","author":"Liu","year":"2024","journal-title":"Helicobacter"},{"issue":"15","key":"10.1016\/j.ejmech.2026.118952_bib146","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1021\/acs.jmedchem.5b00863","article-title":"Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)","volume":"58","author":"Basarab","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejmech.2026.118952_bib147","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40265-025-02255-0","article-title":"Brensocatib: first approval","volume":"86","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib148","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/d41573-025-00108-9","article-title":"Neutrophil-targeting drug seeks first approval in an inflammatory lung disease","volume":"24","author":"Kingwell","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118952_bib149","article-title":"ASPEN: brensocatib's role in advancing bronchiectasis management in adults through neutrophil serine protease inhibition","volume":"6","author":"O'Farrell","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ejmech.2026.118952_bib150","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1021\/acs.jmedchem.6b01127","article-title":"Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986)","volume":"59","author":"Doyle","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib151","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1021\/acs.oprd.4c00309","article-title":"Development of a scalable asymmetric process for the synthesis of selective PDE4B inhibitor nerandomilast (BI 1015550)","volume":"28","author":"Frutos","year":"2024","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2026.118952_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838449","article-title":"BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Herrmann","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118952_bib153","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1165\/rcmb.2024-0614OC","article-title":"Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast","volume":"73","author":"Reininger","year":"2025","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118952_bib154","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/biomedicines14010154","article-title":"Most promising emerging therapies for pulmonary fibrosis: targeting novel pathways","volume":"14","author":"Carriera","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.118952_bib155","first-page":"441","article-title":"Nerandomilast slows progression of pulmonary fibrosis","volume":"21","author":"Papatriantafyllou","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.118952_bib156","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/jop.1998.14.363","article-title":"Selectivity of muscarinic agonists including (+\/-)-aceclidine and antimuscarinics on the human intraocular muscles","volume":"14","author":"Ishikawa","year":"1998","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2026.118952_bib157","series-title":"LENZ Therapeutics Announces US FDA Approval of VIZZ\u2122 for the Treatment of Presbyopia","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118952_bib159","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.bmcl.2005.02.071","article-title":"Synthesis of the optical isomers of a new anticholinergic drug, penehyclidine hydrochloride (8018)","volume":"15","author":"Han","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118952_bib160","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s40265-025-02218-5","article-title":"Acoltremon: first approval","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib161","article-title":"Acoltremon ophthalmic solution 0.003% for signs and symptoms of dry eye disease: results of phase 3 pivotal COMET-2 and COMET-3 studies","author":"Pattar","year":"2025","journal-title":"Ophthalmology, Epub ahead of print"},{"key":"10.1016\/j.ejmech.2026.118952_bib162","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/nm.2264","article-title":"Ocular surface wetness is regulated by TRPM8-dependent cold thermoreceptors of the cornea","volume":"16","author":"Parra","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib163","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/ph11040125","article-title":"TRPM8 channels and dry eye","volume":"11","author":"Yang","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.118952_bib164","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jtos.2022.08.003","article-title":"A randomized, vehicle-controlled, phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1)","volume":"26","author":"Wirta","year":"2022","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.ejmech.2026.118952_bib165","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.ejmech.2026.118952_bib166","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.pain.2013.06.043","article-title":"TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain","volume":"154","author":"Liu","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2026.118952_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.clae.2024.102347","article-title":"Efficacy and safety of transient receptor potential channel modulators for dry eye: a systematic review and meta-analysis","volume":"48","author":"Duan","year":"2025","journal-title":"Contact Lens Anterior Eye"},{"key":"10.1016\/j.ejmech.2026.118952_bib168","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/jcm10020250","article-title":"Topical TRPM8 agonist for relieving neuropathic ocular pain in patients with dry eye: a pilot study","volume":"10","author":"Yoon","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib169","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.ejmech.2026.118952_bib170","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.ejmech.2026.118952_bib171","series-title":"China. CN 117945886 A","article-title":"A synthetic method of menthylformic acid, a key intermediate of WS series cooling agents","author":"Du","year":"2024"},{"key":"10.1016\/j.ejmech.2026.118952_bib172","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell\u2013 and myeloid cell\u2013mediated arthritis","volume":"7","author":"Di Paolo","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118952_bib173","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton's tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib174","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1021\/acsmedchemlett.9b00317","article-title":"Design of potent and selective covalent inhibitors of Bruton's tyrosine kinase targeting an inactive conformation","volume":"10","author":"Pulz","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118952_bib175","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12227","article-title":"Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of Fc\u03b5R1 expression level and omalizumab clinical response","volume":"13","author":"Gimeno","year":"2023","journal-title":"Clin. Transl. Allergy"},{"key":"10.1016\/j.ejmech.2026.118952_bib176","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaci.2025.09.028","article-title":"Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies","volume":"157","author":"Gim\u00e9nez-Arnau","year":"2026","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2026.118952_bib177","doi-asserted-by":"crossref","first-page":"13629","DOI":"10.1021\/acs.jmedchem.2c00921","article-title":"Sebetralstat (KVD900): a potent and selective small molecule Plasma Kallikrein inhibitor featuring a Novel P1 group as a potential oral On-Demand treatment for hereditary angioedema","volume":"65","author":"Davie","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib178","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.anai.2025.10.017","article-title":"Sebetralstat for on-demand treatment of hereditary angioedema in pediatric (2-11y) patients: interim results from confident-kid","volume":"135","author":"Adatia","year":"2025","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ejmech.2026.118952_bib179","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.anai.2025.08.121","article-title":"Satisfaction with Sebetralstat for hae attacks in patients switching from parenteral on-Demand treatments in Konfident-S","volume":"135","author":"O'Connor","year":"2025","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ejmech.2026.118952_bib180","first-page":"389","article-title":"Rilzabrutinib: first approval","volume":"86","author":"Lee","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib181","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1021\/acs.jmedchem.1c01170","article-title":"Discovery of reversible covalent Bruton's tyrosine kinase inhibitors PRN473 and PRN1008 (Rilzabrutinib)","volume":"65","author":"Owens","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib182","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/jamadermatol.2025.0733","article-title":"Rilzabrutinib in antihistamine-refractory chronic spontaneous urticaria","volume":"161","author":"Gim\u00e9nez-Arnau","year":"2025","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ejmech.2026.118952_bib183","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton Tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease","volume":"206","author":"Langrish","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2026.118952_bib184","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2025-2975","article-title":"A randomized, double-blind, placebo-controlled trial of a novel BTK inhibitor (rilzabrutinib) in patients with sickle cell disease (SCD) aged 10\u201365 years: LIBRA study","volume":"146","author":"Ataga","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118952_bib185","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-1260","article-title":"Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent\/chronic immune thrombocytopenia in the long-term extension period of the phase 3 LUNA3 study","volume":"146","author":"Kuter","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118952_bib186","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood.2024027336","article-title":"Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study","volume":"145","author":"Kuter","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118952_bib187","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1021\/acsmedchemlett.2c00431","article-title":"Discovery of paltusotine (CRN00808), a potent, selective, and orally bioavailable non-peptide SST2 agonist","volume":"14","author":"Zhao","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118952_bib188","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40265-025-02260-3","article-title":"Paltusotine: first approval","volume":"86","author":"Lee","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib189","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5582\/ddt.2025.01109","article-title":"Paltusotine: the first selective nonpeptide agonist of somatostatin receptor 2 (SSTR2) for the treatment of acromegaly","volume":"19","author":"Sun","year":"2025","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.ejmech.2026.118952_bib190","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11102-021-01201-z","article-title":"Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers","volume":"25","author":"Madan","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.ejmech.2026.118952_bib192","series-title":"Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and all Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients","year":"2024"},{"key":"10.1016\/j.ejmech.2026.118952_bib193","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.632","article-title":"Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: biomarker analysis results from a phase 2, randomized, parallel-group study","volume":"44","author":"Oviedo Albor","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib194","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1152\/physrev.00052.2017","article-title":"The role of voltage-gated sodium channels in pain signaling","volume":"99","author":"Bennett","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2026.118952_bib195","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40265-025-02178-w","article-title":"Suzetrigine: first approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib196","first-page":"zxaf219","article-title":"Suzetrigine: a novel selective sodium channel inhibitor for pain","author":"Courtney","year":"2025","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2026.118952_bib197","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Ther."},{"key":"10.1016\/j.ejmech.2026.118952_bib198","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/molpharm.124.000944","article-title":"State-dependent inhibition of Nav1.8 sodium channels by VX-150 and VX-548","volume":"106","author":"Vaelli","year":"2024","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118952_bib199","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.tips.2025.02.008","article-title":"Suzetrigine for moderate to severe acute pain","volume":"46","author":"Cho","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.118952_bib200","first-page":"1085","article-title":"Suzetrigine, a non-opioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials","volume":"142","author":"Bertoch","year":"2025","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejmech.2026.118952_bib201","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2147\/JPR.S509144","article-title":"Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study for surgical or non-surgical acute pain","volume":"18","author":"McCoun","year":"2025","journal-title":"J. Pain Res."},{"key":"10.1016\/j.ejmech.2026.118952_bib202","article-title":"Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels, December","author":"Harrison","year":"2022","journal-title":"World Intellectual Property Organization (WIPO). WO 2022\/256660 A1"},{"key":"10.1016\/j.ejmech.2026.118952_bib203","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s40265-025-02208-7","article-title":"Atrasentan: first approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib204","series-title":"Novartis, Novartis Receives FDA Accelerated Approval for Vanrafia\u00ae (Atrasentan), the First and Only Selective Endothelin A Receptor Antagonist for Proteinuria Reduction in Primary Iga Nephropathy (Igan)","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118952_bib205","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/j.ekir.2021.03.388","article-title":"Human renal mesangial cell activation induced by Endothelin-1 or Iga nephropathy patient-derived immune complexes is blocked by selective Eta antagonist Atrasentan","volume":"6","author":"Cox","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ejmech.2026.118952_bib206","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2337\/db15-1413","article-title":"Atrasentan reduces albuminuria by restoring the glomerular Endothelial Glycocalyx barrier in diabetic nephropathy","volume":"65","author":"Boels","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2026.118952_bib207","article-title":"Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy","volume":"6","author":"Kang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118952_bib208","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib209","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1021\/jm9505369","article-title":"2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722","volume":"39","author":"Winn","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118952_bib210","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","article-title":"Delgocitinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib211","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40265-025-02262-1","article-title":"Pan-JAK inhibition across chronic hand eczema and other cutaneous diseases: an updated review on topical delgocitinib","volume":"86","author":"Termini","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib212","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40265-025-02206-9","article-title":"Delgocitinib 20 mg\/g cream: a review in chronic hand eczema","volume":"85","author":"McGuigan","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib213","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdv.20777","article-title":"Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe chronic hand eczema","volume":"39","author":"Tha\u00e7i","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ejmech.2026.118952_bib214","article-title":"Randomized controlled trial of the topical Jak Inhibitor Delgocitinib cream in patients with frontal fibrosing alopecia","author":"Martin","year":"2025","journal-title":"J Invest Dermatol, Epub ahead of print"},{"key":"10.1016\/j.ejmech.2026.118952_bib215","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/acs.oprd.1c00031","article-title":"Stereocontrolled synthesis of delgocitinib, a JAK inhibitor for the treatment of atopic dermatitis","volume":"25","author":"Takiguchi","year":"2021","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2026.118952_bib216","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40265-025-02231-8","article-title":"Advances in pharmacotherapy for menopausal vasomotor symptoms","volume":"85","author":"Young Moss","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib217","doi-asserted-by":"crossref","first-page":"e3221","DOI":"10.1210\/clinem\/dgab108","article-title":"Elinzanetant (NT-814), a neurokinin 1,3 receptor antagonist, reduces estradiol and progesterone in healthy women","volume":"106","author":"Pawsey","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2026.118952_bib218","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.yfrne.2013.07.003","article-title":"Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes","volume":"34","author":"Rance","year":"2013","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.ejmech.2026.118952_bib219","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40265-025-02244-3","article-title":"Elinzanetant: first approval","volume":"86","author":"Lee","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib220","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jama.2024.14618","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials","volume":"332","author":"Pinkerton","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.118952_bib221","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa2415566","article-title":"Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer","volume":"393","author":"Cardoso","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib222","series-title":"Preparation of 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine, Key Intermediate for NT-814","author":"Schloissnigg","year":"2024"},{"key":"10.1016\/j.ejmech.2026.118952_bib223","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1515\/bmc-2013-0001","article-title":"Neurokinin receptors in the gastrointestinal muscle wall: cell distribution and possible roles","volume":"4","author":"Vannucchi","year":"2013","journal-title":"Biomol. Concepts"},{"key":"10.1016\/j.ejmech.2026.118952_bib224","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/apt.17065","article-title":"Clinical trial: a single\u2010centre, randomised, controlled trial of tradipitant on satiation, gastric functions, and serum drug levels in healthy volunteers","volume":"56","author":"Khanna","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118952_bib225","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.563373","article-title":"Tradipitant in the treatment of motion sickness: a randomized, double-blind, placebo-controlled study","volume":"11","author":"Polymeropoulos","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejmech.2026.118952_bib227","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.cgh.2024.01.005","article-title":"The efficacy of tradipitant in patients with diabetic and idiopathic gastroparesis in a phase 3 randomized placebo-controlled clinical trial","volume":"22","author":"Carlin","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2026.118952_bib228","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/gutjnl-2018-316405","article-title":"Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis","volume":"68","author":"Vijayvargiya","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2026.118952_bib229","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.gastro.2020.07.029","article-title":"Efficacy and safety of tradipitant in patients with diabetic and idiopathic gastroparesis in a randomized, placebo-controlled trial","volume":"160","author":"Carlin","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2026.118952_bib230","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(19)40855-X","article-title":"Tradipitant, a novel Nk-1 receptor antagonist, significantly improved nausea and other symptoms of gastroparesis: results of a multicenter, randomized, double-blind, placebo-controlled phase Ii trial","volume":"156","author":"Carlin","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2026.118952_bib231","series-title":"Process Development of a Pyridine-Containing NK-1 Receptor Antagonist","author":"Kopach","year":"2017"},{"key":"10.1016\/j.ejmech.2026.118952_bib232","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nsmb.3129","article-title":"Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab","volume":"22","author":"Scapin","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118952_bib233","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2461191","article-title":"Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties","volume":"17","author":"Seth","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.ejmech.2026.118952_bib234","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.str.2024.07.001","article-title":"Structural basis for the inhibition of \u03b2FXIIa by garadacimab","volume":"32","author":"Drulyte","year":"2024","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.118952_bib236","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.jtho.2025.06.002","article-title":"A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC","volume":"20","author":"Ahn","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib237","article-title":"DATROWAY\u00ae approved in the U.S. as first TROP2 directed therapy for patients with previously treated advanced EGFR-mutated non-small cell lung","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.118952_bib239","series-title":"EMRELISTM (Telisotuzumab vedotin-tllv) Prescribing Information","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118952_bib240","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5582\/ddt.2025.01058","article-title":"Telisotuzumab vedotin: the first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC)","volume":"19","author":"Zhao","year":"2025","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.ejmech.2026.118952_bib243","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein overexpressing, non-squamous, EGFR-wildtype advanced NSCLC: updated analysis of the LUMINOSITY trial","author":"Girard","year":"2026","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ejmech.2026.118952_bib244","series-title":"ENFLONSIA\u2122 (Clesrovimab-cfor) Prescribing Information","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118952_bib245","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40265-025-02224-7","article-title":"Clesrovimab: first approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib246","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1038\/s41467-019-12137-1","article-title":"A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein","volume":"10","author":"Tang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118952_bib248","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2502984","article-title":"Clesrovimab for prevention of RSV disease in healthy infants","volume":"393","author":"Zar","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib249","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMc2506107","article-title":"Clesrovimab in infants and children at increased risk for severe RSV disease","volume":"393","author":"Zar","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib250","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bcp.15002","article-title":"A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma","volume":"88","author":"Singh","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118952_bib251","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2026.03.008","article-title":"Early and sustained efficacy of Depemokimab in type 2 asthma: a pooled analysis of the SWIFT-1\/-2 studies","author":"Wechsler","year":"2026","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.ejmech.2026.118952_bib252","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118952_bib253","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-Yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib254","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.chest.2025.07.007","article-title":"Twice-Yearly depemokimab reduces need for burst oral corticosteroid use in patients with asthma: Posthoc analyses of the phase iii Swift-1\/2 studies","volume":"168","author":"Chupp","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2026.118952_bib255","article-title":"Depemokimab: first approval","author":"Lee","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib256","series-title":"Food and Drug Administration Approves Csl's ANDEMBRY\u00ae (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor Xiia with Once-Monthly Dosing for all Patients from the Start","author":"Csl","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118952_bib257","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118952_bib258","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/all.16351","article-title":"Long\u2010term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: phase 3 open\u2010label extension study","volume":"80","author":"Reshef","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2026.118952_bib259","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2020.152001","article-title":"Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab","volume":"225","author":"Rambaldi","year":"2020","journal-title":"Immunobiology"},{"key":"10.1016\/j.ejmech.2026.118952_bib260","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148688","article-title":"Real world use of narsoplimab in a case of severe HSCT-TMA","volume":"138","author":"Pantin","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118952_bib261","first-page":"2447","article-title":"Narsoplimab, a mannan-binding lectin-associated serine Protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation\u2013associated thrombotic microangiopathy","volume":"40","author":"Khaled","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib262","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of Narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ejmech.2026.118952_bib263","series-title":"Imaavyy (Nipocalimab) Prescribing Information","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118952_bib264","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an Anti\u2010FcRn antibody: Pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first\u2010in\u2010Human study","volume":"105","author":"Ling","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118952_bib265","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2026.118952_bib266","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ibra.70006","article-title":"Nipocalimab\u2010aahu in generalised myasthenia gravis: a new Fc receptor\u2010targeted option for antibody\u2010positive patients","volume":"11","author":"Hussain","year":"2025","journal-title":"Ibrain"},{"key":"10.1016\/j.ejmech.2026.118952_bib267","article-title":"Ltd, anniko\u00ae (PD-1 monoclonal antibody","year":"2025","journal-title":"penpulimab injection)"},{"key":"10.1016\/j.ejmech.2026.118952_bib268","article-title":"Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 antibody, with improved efficacy and low incidence of immune-related adverse events","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118952_bib269","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41392-026-02645-0","article-title":"Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study","volume":"11","author":"Huang","year":"2026","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118952_bib270","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41392-024-01865-6","article-title":"Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118952_bib272","first-page":"993","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-neutralizing IgG2 monoclonal antibody, in healthy volunteers, kidney","volume":"7","author":"Mathur","year":"2022","journal-title":"Int. Rep."},{"key":"10.1016\/j.ejmech.2026.118952_bib273","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2023.1346769","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2024","journal-title":"Front Nephrol"},{"key":"10.1016\/j.ejmech.2026.118952_bib274","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib276","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1016\/j.ekir.2025.09.031","article-title":"Evaluating sibeprenlimab in IgA nephropathy - rationale and baseline data from the VISIONARY trial","volume":"10","author":"Perkovic","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ejmech.2026.118952_bib278","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40265-025-02203-y","article-title":"Fitusiran: first approval","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib279","series-title":"Sanofi, QFITLIA (Fitusiran) Prescribing Information","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118952_bib280","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118952_bib281","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejmech.2026.118952_bib282","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2023021864","article-title":"Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis: the ATLAS-PPX trial","volume":"143","author":"Kenet","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118952_bib283","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ejmech.2026.118952_bib284","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib285","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200325","article-title":"RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia","volume":"2","author":"Gaudet","year":"2023","journal-title":"NEJM Evid."},{"key":"10.1016\/j.ejmech.2026.118952_bib286","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118952_bib288","series-title":"DAWNZERA (Donidalorsen) Prescribing Information","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118952_bib289","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40265-025-02257-y","article-title":"Donidalorsen: first approval","volume":"86","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib290","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/all.15948","article-title":"A phase 2 open\u2010label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema","volume":"79","author":"Petersen","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2026.118952_bib291","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.70206","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of donidalorsen, an antisense oligonucleotide in development for prophylaxis of hereditary angioedema","volume":"15","author":"Diep","year":"2026","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118952_bib294","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s40265-014-0314-5","article-title":"Pembrolizumab: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118952_bib295","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","article-title":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.118952_bib299","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-026-01466-2","article-title":"Linvoseltamab versus real-world international myeloma working group standard-of-care in triple-class exposed relapsed\/refractory multiple myeloma","volume":"16","author":"Kumar","year":"2026","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2026.118952_bib300","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-697","article-title":"Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: initial results from the window of opportunity phase 1\/2 LINKER-MM4 trial","volume":"146","author":"Orlowski","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118952_bib301","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clml.2024.11.012","article-title":"Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives","volume":"25","author":"Waldschmidt","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejmech.2026.118952_bib302","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","article-title":"A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells","volume":"5","author":"DiLillo","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejmech.2026.118952_bib303","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.114.214221","article-title":"Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering","volume":"350","author":"Mitchell","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.118952_bib304","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1093\/eurheartj\/ehaf606","article-title":"The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications","volume":"46","author":"Ballantyne","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2026.118952_bib305","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","article-title":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial","volume":"44","author":"Raal","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2026.118952_bib306","article-title":"Lerodalcibep: another crucial addition to the dyslipidaemia arsenal","volume":"26","author":"Jamialahmadi","year":"2025","journal-title":"Rev. Cardiovasc. Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:35:21Z","timestamp":1783182921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426003971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":282,"alternative-id":["S0223523426003971"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118952","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New drugs approved by the FDA in 2025: Synthesis and clinical applications","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118952"}}